Inflammatory IL‐1β‐driven JNK activation in stage III melanoma
暂无分享，去创建一个
[1] N. Ebelt,et al. c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade. , 2013, Genes & cancer.
[2] C. Tournier. The 2 Faces of JNK Signaling in Cancer. , 2013, Genes & cancer.
[3] G. Lizée,et al. Constitutive Aberrant Endogenous Interleukin-1 Facilitates Inflammation and Growth in Human Melanoma , 2011, Molecular Cancer Research.
[4] M. Bogoyevitch,et al. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. , 2010, Biochimica et biophysica acta.
[5] B. Salh. c-Jun N-terminal kinases as potential therapeutic targets , 2007, Expert opinion on therapeutic targets.
[6] L. Broemeling,et al. Tumor iNOS predicts poor survival for stage III melanoma patients , 2006, International journal of cancer.
[7] Chao Zhang,et al. Chemical genetic analysis of the time course of signal transduction by JNK. , 2006, Molecular cell.
[8] A. Manning,et al. Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.